NCT03706118

Physiologic Volume and Atrophy of Brain and Spinal Cord Measured by Magnetic Resonance Imaging

Status unknown NA Last updated 29 July 2020

What this trial tests

NA trial testing Magnetic resonance imaging in Cognitive Change in 102 participants. Status unknown.

Timeline

15 March 2018

Primary endpoint
14 September 2018

1 November 2021

Quick facts

Lead sponsor	Dana Horakova
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	basic science
Enrollment	102
Start date	15 March 2018
Primary completion	14 September 2018
Estimated completion	1 November 2021
Sites	1 location across Czechia

Drugs / interventions tested

• Magnetic resonance imaging

Conditions studied

• Cognitive Change — all drugs for Cognitive Change →
• Atrophy Brain — all drugs for Atrophy Brain →
• Atrophy; Spinal Cord — all drugs for Atrophy; Spinal Cord →
• Multiple Sclerosis — all drugs for Multiple Sclerosis →

Sponsor

Dana Horakova

Who can join

Adults 18 to 60, any sex, with Cognitive Change or Atrophy Brain. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Spinal cord (SC) involvement is prevalent in multiple sclerosis (MS) and contributes importantly to disease progression. To be able reliably evaluate spinal cord volume and its changes in MS patients we need to understand variability of these parameters in sex and age matched healthy controls (HC). To date, no generally available data about these parameters in HC are available.

The objective of this study is to investigate age and sex matched HC by MRI to get the basic set of the data representing both cross sectional values and its longitudinal changes.

The present study will also investigate different strategies how to normalize the absolute spinal cord and brain volume data, what is a relationship between spinal cord volume and brain volume and what is the best protocol to be used in a routine clinical practice.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

1. Periventricular gradient of T₁ tissue alterations in multiple sclerosis.
   Vaneckova M, Piredda GF, Andelova M, Krasensky J, et al · · 2022 · cited 18× · PMID 35561554 · DOI 10.1016/j.nicl.2022.103009
2. Prognostic value of single-subject grey matter networks in early multiple sclerosis.
   Fleischer V, Gonzalez-Escamilla G, Pareto D, Rovira A, et al · · 2024 · cited 17× · PMID 37642541 · DOI 10.1093/brain/awad288
3. Oxidative Stress Markers in Cerebrospinal Fluid of Newly Diagnosed Multiple Sclerosis Patients and Their Link to Iron Deposition and Atrophy.
   Burgetova A, Dusek P, Uher T, Vaneckova M, et al · · 2022 · cited 13× · PMID 35741175 · DOI 10.3390/diagnostics12061365
4. Disentangling Neurodegeneration From Aging in Multiple Sclerosis Using Deep Learning: The Brain-Predicted Disease Duration Gap.
   Pontillo G, Prados F, Colman J, Kanber B, et al · · 2024 · cited 9× · PMID 39496109 · DOI 10.1212/wnl.0000000000209976
5. Quantitative brain morphometry identifies cerebellar, cortical, and subcortical gray and white matter atrophy in late-onset Tay-Sachs disease.
   Májovská J, Nestrašil I, Ahmed A, Bondy MT, et al · · 2024 · cited 5× · PMID 38112342 · DOI 10.1002/jimd.12700
6. CSF Markers of Oxidative Stress Are Associated with Brain Atrophy and Iron Accumulation in a 2-Year Longitudinal Cohort of Early MS.
   Burgetova A, Dusek P, Uher T, Vaneckova M, et al · · 2023 · cited 4× · PMID 37373196 · DOI 10.3390/ijms241210048